Berkowitz Living Laboratory Collaboration

Publications

Scientists in the Berkowitz Living Laboratory Collaboration have published landmark research on the effectiveness and safety of coronavirus vaccinations in real world settings. This research has been published in leading scientific journals, including The New England Journal of Medicine, The Lancet and Nature Medicine, and was used by governments and health authorities to directly inform policy and improve pandemic response.

Dagan N, Devons-Sberro S, Paz Z, Zoller L, Sommer A, Shaham G, Shahar N, Ohana R, Weinstein O, Netzer D, Kotler A, Balicer R. Evaluation of AI Solutions in Health Care Organizations — The OPTICA Tool. NEJM AI. 2024 Aug 14. doi:10.1056/AIcs2300269.

Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B, Balicer RD. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. The New England Journal of Medicine. 2021 Apr 15;384(15):1412-1423. doi: 10.1056/NEJMoa2101765.

Barda N, Dagan N, Balicer RD. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. Reply. The New England Journal of Medicine. 2021 May 20;384(20):1970. doi: 10.1056/NEJMc2104281.

Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, Hernán MA, Lipsitch M, Kohane I, Netzer D, Reis BY, Balicer RD. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. The New England Journal of Medicine. 2021 Sep 16;385(12):1078-1090. doi: 10.1056/NEJMoa2110475.

Dagan N, Barda N, Biron-Shental T, Makov-Assif M, Key C, Kohane IS, Hernán MA, Lipsitch M, Hernandez-Diaz S, Reis BY, Balicer RD. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. Nature Medicine. 2021 Oct;27(10):1693-1695. doi: 10.1038/s41591-021-01490-8.

Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, Grinberg T, Auster O, Dagan N, Balicer RD, Kornowski R. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. The New England Journal of Medicine. 2021 Oct 6:NEJMoa2110737. doi: 10.1056/NEJMoa2110737.

Reis BY, Barda N, Leshchinsky M, Kepten E, Hernán MA, Lipsitch M, Dagan N, Balicer RD. Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents. The New England Journal of Medicine. 2021 Oct 20:NEJMc2114290. doi: 10.1056/NEJMc2114290.

Dagan N, Barda N, Balicer RD. Adverse Effects after BNT162b2 Vaccine and SARS-CoV-2 Infection, According to Age and Sex. The New England Journal of Medicine. 2021 Oct 27. doi: 10.1056/NEJMc2115045.

Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, Reis BY, Balicer RD. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. The Lancet. 2021 Oct 29. doi: 10.1016/S0140-6736(21)02249-2.

Hayek S, Shaham G, Ben-Shlomo Y, Kepten E, Dagan N, Nevo D, Lipsitch M, Reis BY, Balicer RD, Barda N. Indirect protection of children from SARS-CoV-2 infection through parental vaccination. Science. 2022 Jan 27:eabm3087. doi: 10.1126/science.abm3087.

Barda N, Dagan N. The role of observational studies based on secondary data in studying SARS-CoV-2 vaccines. Clinical Microbiology and Infection. 2022 Mar; 28(3): 313–314. Published online 2021 Dec 11. doi: 10.1016/j.cmi.2021.12.006.

Cohen-Stavi C, Magen O,  Barda N, Yaron S, Peretz A, Netzer D, Giaquinto C, Judd A, Leibovici L, Hernán M, Lipsitch M, Reis B, et al. BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age. N Engl J Med July 21, 2022; 387:227-236 doi: 10.1056/NEJMoa2205011.